Skip to content

PolitiKit

Lobbying by Pharmascience Inc.: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.

← Lobbying

Corporation

Pharmascience Inc.

Meetings this Parliament
175
With MPs
20
Since Nov 2021
212
Active registrations
1

Most recent reported meeting: Oct 13, 2026.

Registrations in effect

In-house (corporation) In effect since Oct 20, 2026 Receives government funding

Filed by David Goodman, Chief Executive Officer

Lobbyists

  • David Goodman · Executive Chairman
  • Julie Seïde · Director, Government Affairs
  • Ken Gagnon · Senior Manager, Government Affairs
  • Morris Goodman · Co-Founder

Institutions they may lobby: Finance Canada (FIN), Global Affairs Canada (GAC), Health Canada (HC), House of Commons, Innovation, Science and Economic Development Canada (ISED), Prime Minister's Office (PMO), Privy Council Office (PCO), Public Services and Procurement Canada (PSPC), Transport Canada (TC)

What they're lobbying on (8)
  • Policies aimed at reinforcing pharmaceutical supply chain.
  • Discussion regarding the launch of new branded product in the rare disease space
  • Improvements to the supports offered by the federal government to support R&D; in particular, generic drug research and development.
  • Seeking support from the Strategic Innovation Fund Program for support of biomanufacturing expansion project.
  • Policies aimed at facilitating generic drug repurposing.
  • Discussion on the opioid crisis and the Health minister's expectations from pharmaceutical manufacturers
  • Discussion of regulatory impediments to the launch of pediatric formulations of branded and generic products.
  • Discussion of a possible Therapeutics Products Directorate ("TPD") workstream on complex generics regulatory pathways.

Registration 725814-234102-38. Look it up in the official Registry

Reported meetings

Spreadsheet

Filed by David Goodman (205), Martin Arès (7).

  • Reported by David Goodman · In-house (corporation)

    • Jean-Francois Courtois · Directeur exécutif, Innovation, Science and Economic Development Canada (ISED)
    • Rodrigo Arancibia · Senior Director, Innovation, Science and Economic Development Canada (ISED)
    • Alison McConnell · Directrice adjointe, Innovation, Science and Economic Development Canada (ISED)
    • Inga Pusca · Gestionnaire princ. d'investissements p. int., Innovation, Science and Economic Development Canada (ISED)
    and 1 more
    • Nadeen Abd El Aal · Analyste princ. de politiques, Innovation, Science and Economic Development Canada (ISED)
    Seeking support from the Strategic Innovation Fund Program for support of biomanufacturing expansion project.

    Official report

  • Reported by David Goodman · In-house (corporation)

    • Jean-Francois Courtois · Directeur exécutif, Innovation, Science and Economic Development Canada (ISED)
    • Rodrigo Arancibia · Senior Director, Innovation, Science and Economic Development Canada (ISED)
    • Alison McConnell · Directrice adjointe, Innovation, Science and Economic Development Canada (ISED)
    • Inga Pusca · Gestionnaire princ. d'investissements p. int., Innovation, Science and Economic Development Canada (ISED)
    and 1 more
    • nadeen Abd El Aal · Analyste princ. de politiques, Innovation, Science and Economic Development Canada (ISED)
    Seeking support from the Strategic Innovation Fund Program for support of biomanufacturing expansion project.

    Official report

  • Reported by David Goodman · In-house (corporation)

    • Mackenzy Metcalfe · Conseillère en politiques, Finance Canada (FIN)
    Policies aimed at reinforcing pharmaceutical supply chain.

    Official report

  • Reported by David Goodman · In-house (corporation)

    • Mackenzy Metcalfe · Conseillère en politiques, Finance Canada (FIN)
    Policies aimed at reinforcing pharmaceutical supply chain.

    Official report

  • Reported by David Goodman · In-house (corporation)

    • Rodrigo Arancibia · Senior Director, Innovation, Science and Economic Development Canada (ISED)
    Seeking support from the Strategic Innovation Fund Program for support of biomanufacturing expansion project.

    Official report

  • Reported by David Goodman · In-house (corporation)

    • Rodrigo Arancibia · Senior Director, Innovation, Science and Economic Development Canada (ISED)
    Seeking support from the Strategic Innovation Fund Program for support of biomanufacturing expansion project.

    Official report

  • Reported by David Goodman · In-house (corporation)

    • Rodrigo Arancibia · Senior Director, Innovation, Science and Economic Development Canada (ISED)
    Seeking support from the Strategic Innovation Fund Program for support of biomanufacturing expansion project.

    Official report

  • Reported by David Goodman · In-house (corporation)

    • Rodrigo Arancibia · Senior Director, Innovation, Science and Economic Development Canada (ISED)
    Seeking support from the Strategic Innovation Fund Program for support of biomanufacturing expansion project. Read more

    Policies aimed at reinforcing pharmaceutical supply chain.

    Official report

  • Reported by David Goodman · In-house (corporation)

    • Sandenga Yeba · Deputy chief of staff and policy director, Health Canada (HC)
    Policies aimed at reinforcing pharmaceutical supply chain.

    Official report

  • Reported by David Goodman · In-house (corporation)

    • Sandenga Yeba · Deputy chief of staff and policy director, Health Canada (HC)
    Policies aimed at reinforcing pharmaceutical supply chain.

    Official report

  • Reported by David Goodman · In-house (corporation)

    • Sandenga Yeba · Deputy chief of staff and policy director, Health Canada (HC)
    Policies aimed at facilitating generic drug repurposing.

    Official report

  • Reported by David Goodman · In-house (corporation)

    • Manuela Tomic · Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
    Policies aimed at reinforcing pharmaceutical supply chain.

    Official report

  • Reported by David Goodman · In-house (corporation)

    • Sandenga Yeba · Deputy chief of staff and policy director, Health Canada (HC)
    Policies aimed at reinforcing pharmaceutical supply chain.

    Official report

  • Reported by David Goodman · In-house (corporation)

    • Manuela Tomic · Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
    • Paul Moen · Chief of Staff, Innovation, Science and Economic Development Canada (ISED)
    • Cédrick Devedeux Delorme · Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
    Policies aimed at reinforcing pharmaceutical supply chain.

    Official report

  • Reported by David Goodman · In-house (corporation)

    • Sandenga Yeba · Deputy chief of staff and policy director, Health Canada (HC)
    Policies aimed at reinforcing pharmaceutical supply chain.

    Official report

  • Reported by David Goodman · In-house (corporation)

    • Sandenga Yeba · Deputy chief of staff and policy director, Health Canada (HC)
    Policies aimed at reinforcing pharmaceutical supply chain.

    Official report

  • Reported by David Goodman · In-house (corporation)

    • Manuela Tomic · Conseillère politique, Innovation, Science and Economic Development Canada (ISED)
    • Cédrick Devedeux Delorme · Directeur adjoint des Opérations, Innovation, Science and Economic Development Canada (ISED)
    Seeking support from the Strategic Innovation Fund Program for support of biomanufacturing expansion project.

    Official report

  • Reported by David Goodman · In-house (corporation)

    • Élyse Moisan · Conseiller politique, Finance Canada (FIN)
    Policies aimed at reinforcing pharmaceutical supply chain.

    Official report

  • Reported by David Goodman · In-house (corporation)

    • Rodrigo Arancibia · Senior Director, Innovation, Science and Economic Development Canada (ISED)
    Seeking support from the Strategic Innovation Fund Program for support of biomanufacturing expansion project.

    Official report

  • Reported by David Goodman · In-house (corporation)

    • Sandenga Yeba · Deputy chief of staff and policy director, Health Canada (HC)
    Discussion regarding the launch of new branded product in the rare disease space

    Official report

  • Reported by David Goodman · In-house (corporation)

    • Mackenzy Metcalfe · Conseillère en politiques, Finance Canada (FIN)
    Policies aimed at reinforcing pharmaceutical supply chain.

    Official report

  • Reported by David Goodman · In-house (corporation)

    • Manuela Tomic · Conseillère politique, Innovation, Science and Economic Development Canada (ISED)
    Policies aimed at reinforcing pharmaceutical supply chain.

    Official report

  • Reported by David Goodman · In-house (corporation)

    • Kerry Robinson · Director General, Health Canada (HC)
    Policies aimed at reinforcing pharmaceutical supply chain.

    Official report

  • Reported by David Goodman · In-house (corporation)

    • Rodrigo Arancibia · Directeur général, Innovation, Science and Economic Development Canada (ISED)
    Policies aimed at reinforcing pharmaceutical supply chain.

    Official report

  • Reported by David Goodman · In-house (corporation)

    • Cédrick Devedeux Delorme · Conseiller Principal, Innovation, Science and Economic Development Canada (ISED)
    • David McFarlane · Directeur adjoint, Innovation, Science and Economic Development Canada (ISED)
    Policies aimed at reinforcing pharmaceutical supply chain.

    Official report

From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.